Growth in this market is primarily driven by the rising incidence of infectious diseases; technological advancements towards the development of rapid AST technologies; increased funding, research grants, and public-private investments; growing government initiatives to detect and control antimicrobial-resistant species; and the emergence of multidrug resistance due to drug abuse.
Based on application, the antimicrobial susceptibility testing market has been segmented into the market is segmented into clinical diagnostics, drug discovery and development, epidemiology, and other applications. Significant market growth in the clinical diagnostics segment can be attributed to the rising burden of infectious diseases, the growing burden of antimicrobial resistance, and new product launches in the market.
Based on the product, the antimicrobial susceptibility testing market is segmented into automated laboratory instruments, manual antimicrobial susceptibility testing products, culture and growth media, and consumables. The manual susceptibility testing products segment is further divided into susceptibility testing disks, MIC strips, and susceptibility testing plates. Among the manual antimicrobial susceptibility testing products, the susceptibility testing disks segment held a major share of the market in 2019.
Based on type, the market has been segmented into the antibacterial susceptibility testing, antifungal susceptibility testing, antiparasitic susceptibility testing, and susceptibility testing types. Among these, the antibacterial susceptibility testing segment dominated the market in 2019. The major share of the segment is attributed to the presence of regulatory guidelines to streamline the process of antibacterial susceptibility testing, technological advancements, and the rising burden of antibacterial resistance in developing as well as developed countries.
Opportunity: Awareness initiatives for antimicrobial resistance and its control
Antimicrobial susceptibility tests play a significant role in detecting the resistance of bacteria to antibiotics. Healthcare authorities are increasingly becoming aware of the significance of antimicrobial susceptibility to ensure the efficacy and safety of AST methods. Various initiatives—for instance, the Global Sepsis Alliance (GSA), a non-profit organization located in the US, works to support over one million caregivers in more than 70 countries and increase awareness about sepsis and its management. Likewise, in the US, the CDC launched a new website, Antibiotic / Antimicrobial Resistance (AR / AMR), to increase AMR awareness and support the early recognition, diagnosis, and treatment of antibiotic resistance. Along with this, various local government and intergovernmental organizations such as the WHO, EU, Transatlantic Task Force on Antimicrobial Resistance (TATFAR), and Global Health Security Agenda (GHSA) are developing and implementing plans and efforts to tackle antimicrobial resistance.
Challenge: Complex regulatory frameworks that delay antimicrobial testing approvals
Among the major challenges faced by the AST market is the time lapse between establishing clinical breakpoints, approval of new antimicrobial agents, and the inclusion of these agents in antimicrobial susceptibility testing. The FDA establishes these breakpoints when drug manufacturers submit individual new drug applications or when device manufacturers submit requests to revise the breakpoints. Furthermore, the unavailability of clinical breakpoints for certain drugs is also limiting the adoption of AST products.
North America, comprising the US and Canada, accounted for the largest share of the Antimicrobial Susceptibility Test Market in 2019. Technological advancements in rapid antimicrobial susceptibility testing systems, rising incidence of infectious diseases (such as AIDS, tuberculosis, and pertussis), and government support for antimicrobial resistance-related research are the major factors driving market growth in North America. As AST through conventional methods is a lengthy process, customers in North America are moving towards rapid AST techniques, which require minimal reagents. This trend will have a positive impact on the automated instruments market.
bioMérieux SA (France), Becton, Dickinson and Company (US), Thermo Fisher Scientific (US), Danaher Corporation (US), Bio-Rad Laboratories, Inc. (US), Bruker (US), Roche Diagnostics Limited (Switzerland), Accelerate Diagnostics, Inc. (US), Merck KGaA (US), Hi-Media Laboratories (India), Liofilchem S.r.l. (Italy), Alifax S.r.l. (Italy), Creative Diagnostics (US), Synbiosis (UK), Bioanalyse (Turkey), ZHUHAI DL BIOTECH Co., Ltd. (China), ELITechGroup (France), Mast Group Ltd. (UK), CONDALAB (Spain), Genefluidics, Inc. (US), Biotron Ltd (Australia), InvivoGen (US), MP Biomedicals (US), QuantaMatrix Inc. (South Korea), and PML Microbiologicals Inc. (US), among others are some of the major players operating in the global AST market.
Contact: Mr. Aashish Mehra MarketsandMarkets™ INC. 630 Dundee Road Suite 430 Northbrook, IL 60062 USA: +1-888-600-6441 Email: email@example.com
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including: